Literature DB >> 19275543

The role of the RhoA/rho-kinase pathway in pulmonary hypertension.

Bobby D Nossaman1, Philip J Kadowitz.   

Abstract

The small GTP-binding protein, RhoA, and its downstream effector protein, rho-kinase, have been implicated in the pathogenesis of a number of cardiovascular diseases. The activation of rho-kinase is involved in the development of increased vascular tone, endothelial dysfunction, inflammation, and restenosis; and that the inhibition of rho-kinase has been shown to have a beneficial effect in a variety of cardiovascular disorders. It is our hypothesis that rho-kinase inhibitors promote vasodilation independent of the mechanism that increases vasoconstrictor tone and moreover, the RhoA/rho-kinase pathway has a role in the regulation of smooth muscle tone under physiological conditions. The objective of this review is to improve our current understanding of the role of RhoA/rho-kinase pathway in the regulation of vasoconstrictor tone and the use of rho-kinase inhibitors in the treatment of cardiovascular disorders with an emphasis on pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275543     DOI: 10.2174/157016309787581057

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  8 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01

3.  S1P2 receptor-dependent Rho-kinase activation mediates vasoconstriction in the murine pulmonary circulation induced by sphingosine 1-phosphate.

Authors:  William S Szczepaniak; Bruce R Pitt; Bryan J McVerry
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-30       Impact factor: 5.464

4.  Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase.

Authors:  Anna Klinke; Eva Berghausen; Kai Friedrichs; Simon Molz; Denise Lau; Lisa Remane; Matthias Berlin; Charlotte Kaltwasser; Matti Adam; Dennis Mehrkens; Martin Mollenhauer; Kashish Manchanda; Thorben Ravekes; Gustavo A Heresi; Metin Aytekin; Raed A Dweik; Jan K Hennigs; Lukas Kubala; Erik Michaëlsson; Stephan Rosenkranz; Tanja K Rudolph; Stanley L Hazen; Hans Klose; Ralph T Schermuly; Volker Rudolph; Stephan Baldus
Journal:  JCI Insight       Date:  2018-06-07

5.  8,9-Epoxyeicosatrienoic acid analog protects pulmonary artery smooth muscle cells from apoptosis via ROCK pathway.

Authors:  Jun Ma; Lei Zhang; Shanshan Li; Shulin Liu; Cui Ma; Weiyang Li; J R Falck; Vijay L Manthati; D Sudarshan Reddy; Meetha Medhora; Elizabeth R Jacobs; Daling Zhu
Journal:  Exp Cell Res       Date:  2010-05-21       Impact factor: 3.905

Review 6.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

7.  Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Authors:  Ahmad Sharanek; Audrey Burban; Matthew Burbank; Rémy Le Guevel; Ruoya Li; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

8.  Effects of blood oxygen saturation on pulmonary artery remodeling in an in vitro perfusion circuit model.

Authors:  Yao Liu; Bin Wen; Fengwen Zhang; Xiang-Bin Pan
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.